Joint modeling of tumor dynamics and progression‐free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I–II trials
Cerou, Marc, Thai, Hoai‐Thu, Deyme, Laure, Fliscounakis‐Huynh, Sophie, Comets, Emmanuelle, Cohen, Patrick, Cartot‐Cotton, Sylvaine, Veyrat‐Follet, Christine
Published in CPT: pharmacometrics and systems pharmacology (01.06.2024)
Published in CPT: pharmacometrics and systems pharmacology (01.06.2024)
Get full text
Journal Article
AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer
Bardia, Aditya, Chandarlapaty, Sarat, Linden, Hannah M., Ulaner, Gary A., Gosselin, Alice, Cartot-Cotton, Sylvaine, Cohen, Patrick, Doroumian, Séverine, Paux, Gautier, Celanovic, Marina, Pelekanou, Vasiliki, Ming, Jeffrey E., Ternès, Nils, Bouaboula, Monsif, Lee, Joon Sang, Bauchet, Anne-Laure, Campone, Mario
Published in Nature communications (15.07.2022)
Published in Nature communications (15.07.2022)
Get full text
Journal Article
First‐in‐human trial of the PI3Kβ‐selective inhibitor SAR260301 in patients with advanced solid tumors
Bédard, Philippe L., Davies, Michael A., Kopetz, Scott, Juric, Dejan, Shapiro, Geoffrey I., Luke, Jason J., Spreafico, Anna, Wu, Bin, Castell, Christelle, Gomez, Corinne, Cartot‐Cotton, Sylvaine, Mazuir, Florent, Dubar, Michel, Micallef, Sandrine, Demers, Brigitte, Flaherty, Keith T.
Published in Cancer (15.01.2018)
Published in Cancer (15.01.2018)
Get full text
Journal Article
Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically‐based pharmacokinetic modelling: application to docetaxel
Thai, Hoai‐Thu, Mazuir, Florent, Cartot‐Cotton, Sylvaine, Veyrat‐Follet, Christine
Published in British journal of clinical pharmacology (01.09.2015)
Published in British journal of clinical pharmacology (01.09.2015)
Get full text
Journal Article
AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer
Bardia, Aditya, Cortes, Javier, Hurvitz, Sara A., Delaloge, Suzette, Iwata, Hiroji, Shao, Zhi-Ming, Kanagavel, Dheepak, Cohen, Patrick, Liu, Qianying, Cartot-Cotton, Sylvaine, Pelekanou, Vasiliki, O’Shaughnessy, Joyce
Published in Therapeutic advances in medical oncology (2022)
Published in Therapeutic advances in medical oncology (2022)
Get full text
Journal Article
Abstract OT-09-11: AMEERA-4, a phase 2 window study of SAR439859 vs letrozole in post-menopausal women with newly diagnosed estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer
Campone, Mario, Herold, Christina, Wang, Qiuyan, Pelekanou, Vasiliki, Cartot-Cotton, Sylvaine, Ling, Bethany
Published in Cancer research (Chicago, Ill.) (15.02.2021)
Published in Cancer research (Chicago, Ill.) (15.02.2021)
Get full text
Journal Article
Phase II preoperative window study of SAR439859 versus letrozole in post-menopausal women with newly diagnosed estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer
Campone, Mario, Herold, Christina Isabella, Wang, Qiuyan, Pelekanou, Vasiliki, Cartot-Cotton, Sylvaine, Ling, Bethany
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
Abstract OT2-11-03: AMEERA-1 : Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) PIK3CA -mutated advanced breast cancer
Campone, Mario, Bardia, Aditya, Kabos, Peter, Chandarlapaty, Sarat, Neven, Patrick, Boni, Valentina, Lord, Simon, Cartot-Cotton, Sylvaine, Celanovic, Marina, Gosselin, Alice, Pelekanou, Vasiliki, Linden, Hannah M
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Get full text
Journal Article
Abstract OT2-11-02: Ameera-1 Arm 4: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with everolimus in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer
Campone, Mario, Neven, Patrick, Petrakova, Katarina, Braga, Sofia, Celanovic, Marina, Cohen, Patrick, Gosselin, Alice, Cartot-Cotton, Sylvaine, Pelekanou, Vasiliki, Boni, Valentina
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Get full text
Journal Article
Abstract OT2-11-08: AMEERA-5 : A randomized, double-blind phase 3 study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer
Bardia, Aditya, Cortes, Javier, Hurvitz, Sara, Delaloge, Suzette, Iwata, Hiroji, Shao, Zhi-Ming, Kanagavel, Dheepak, Cohen, Patrick, Liu, Qianying, Cartot-Cotton, Sylvaine, Pelekanou, Vasiliki, O’Shaughnessy, Joyce
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Get full text
Journal Article
Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5
Cortés, Javier, Hurvitz, Sara A, O'Shaughnessy, Joyce, Delaloge, Suzette, Iwata, Hiroji, Rugo, Hope S, Neven, Patrick, Kanagavel, Dheepak, Cohen, Patrick, Paux, Gautier, Cartot-Cotton, Sylvaine, Stefanova-Urena, Maya, Deyme, Laure, Aouni, Jihane, Sebastien, Bernard, Bardia, Aditya
Published in Journal of clinical oncology (01.08.2024)
Published in Journal of clinical oncology (01.08.2024)
Get full text
Journal Article
AMEERA-5: A randomized, double-blind phase III study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer
Bardia, Aditya, Cortes, Javier, Hurvitz, Sara A., Delaloge, Suzette, Iwata, Hiroji, Zhimin, Shao, Kanagavel, Dheepak, Cohen, Patrick, Liu, Qianying, Cartot-Cotton, Sylvaine, Pelekanou, Vasiliki, O'Shaughnessy, Joyce
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
Abstract OT-09-09: AMEERA-3, a phase 2 trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (her2−), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies
Tolaney, Sara, Cicin, Irfan, Betancourt, Rafael, Chan, Arlene, Kaen, Diego, Kaufman, Peter, Delaloge, Suzette, Liu, Qianying, Cartot-Cotton, Sylvaine, Amrate, Amele, Pelekanou, Vasiliki, Cuff, Katharine
Published in Cancer research (Chicago, Ill.) (15.02.2021)
Published in Cancer research (Chicago, Ill.) (15.02.2021)
Get full text
Journal Article
Abstract OT2-11-04: Ameera-1 Arm 5: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with abemaciclib in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer
Campone, Mario, Chandarlapaty, Sarat, Bardia, Aditya, Neven, Patrick, Petrakova, Katarina, Kabos, Peter, Boni, Valentina, Braga, Sofia, Celanovic, Marina, Cohen, Patrick, Gosselin, Alice, Cartot-Cotton, Sylvaine, Pelekanou, Vasiliki, Linden, Hannah
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Get full text
Journal Article
Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies
Tolaney, Sara M., Cicin, Irfan, Betancourt, Rafael, Chan, Arlene, Kaen, Diego, Kaufman, Peter A., Delaloge, Suzette, Liu, Qianying, Cartot-Cotton, Sylvaine, Amrate, Amele, Pelekanou, Vasiliki, Cuff, Katharine Ellen
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC)
Chandarlapaty, Sarat, Linden, Hannah M., Neven, Patrick, Petrakova, Katarina, Bardia, Aditya, Kabos, Peter, Braga, Sofia A. D. S., Boni, Valentina, Gosselin, Alice, Cartot-Cotton, Sylvaine, Doroumian, Séverine, Celanovic, Marina, Cohen, Patrick, Paux, Gautier, Campone, Mario
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
Modifications of physical and functional integrity of the blood-brain barrier in an inducible mouse model of neurodegeneration
Taccola, Camille, Barneoud, Pascal, Cartot-Cotton, Sylvaine, Valente, Delphine, Schussler, Nathalie, Saubaméa, Bruno, Chasseigneaux, Stéphanie, Cochois, Véronique, Mignon, Virginie, Curis, Emmanuel, Lochus, Murielle, Nicolic, Sophie, Dodacki, Agnès, Cisternino, Salvatore, Declèves, Xavier, Bourasset, Fanchon
Published in Neuropharmacology (15.06.2021)
Published in Neuropharmacology (15.06.2021)
Get full text
Journal Article
High brain distribution of a new central nervous system drug candidate despite its P-glycoprotein-mediated efflux at the mouse blood-brain barrier
Taccola, Camille, Cartot-Cotton, Sylvaine, Valente, Delphine, Barneoud, Pascal, Aubert, Catherine, Boutet, Valérie, Gallen, Fabienne, Lochus, Murielle, Nicolic, Sophie, Dodacki, Agnès, Smirnova, Maria, Cisternino, Salvatore, Declèves, Xavier, Bourasset, Fanchon
Published in European journal of pharmaceutical sciences (30.05.2018)
Published in European journal of pharmaceutical sciences (30.05.2018)
Get full text
Journal Article
Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours
Van Cutsem, Eric, Khayat, David, Verslype, Chris, Billemont, Bertrand, Tejpar, Sabine, Meric, Jean-Baptiste, Soussan-Lazard, Karen, Assadourian, Sylvie, Cartot-Cotton, Sylvaine, Rixe, Olivier
Published in European journal of cancer (1990) (01.01.2013)
Published in European journal of cancer (1990) (01.01.2013)
Get full text
Journal Article
First-in-human trial of the PI3K[beta]-selective inhibitor SAR260301 in patients with advanced solid tumors
Bedard, Philippe L, Davies, Michael A, Kopetz, Scott, Juric, Dejan, Shapiro, Geoffrey I, Luke, Jason J, Spreafico, Anna, Wu, Bin, Castell, Christelle, Gomez, Corinne, Cartot-Cotton, Sylvaine, Mazuir, Florent, Dubar, Michel, Micallef, Sandrine, Demers, Brigitte, Flaherty, Keith T
Published in Cancer (01.01.2018)
Published in Cancer (01.01.2018)
Get full text
Journal Article